Skip to main content
profile image
Selected Works of Julia Chapman, MD, FACOG
Article
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
Journal of Clinical Oncology (2020)
  • Jung-min Lee, National Institutes of Health
  • Richard G. Moore, University of Rochester
  • Sharad A. Ghamande, Georgia Regents University
  • Min S. Park, Swedish Cancer Institute, Seattle, WA;
  • John Paul Diaz, Miami Cancer Institute, Miami, FL;
  • Julia A. Chapman, University of Kansas
  • James Erasmus Kendrick, Advent Health Orlando, Orlando, FL;
  • Brian M. Slomovitz, University of Miami
  • Krishnansu Sujata Tewari, University of California, Irvine
  • Elizabeth S. Lowe, AstraZeneca
  • Tsveta Milenkova, AstraZeneca
  • Sanjeev Kumar, AstraZeneca
  • Mike Dymond, AstraZeneca
  • Iwanka Kozarewa, AstraZeneca
  • Joyce F. Liu, Harvard University
Link
Disciplines
Publication Date
May 25, 2020
DOI
10.1200/JCO.2020.38.15_SUPPL.6056
Citation Information
Jung-min Lee, Richard G. Moore, Sharad A. Ghamande, Min S. Park, et al.. "Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial." Journal of Clinical Oncology Vol. 38 (2020) p. 6056 - 6056
Available at: http://works.bepress.com/julia-chapman/3/